TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03190772

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: The placebo nasal spray consists of sesame oil and does not contain any active drug.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: The placebo nasal spray consists of sesame oil and does not contain any active drug.

Intervention type: OTHER
Group type: OTHER
Intervention: Film sequence
Description: All groups watch the film sequence that is supposed to induce sadness.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Film sequence
Description: All groups watch the film sequence that is supposed to induce sadness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Film sequence
Description: All groups watch the film sequence that is supposed to induce sadness.
Study: NCT00841152

Intervention type: DEVICE
Intervention: Bioactive glass
Description: Surgical implantation

Intervention type: DEVICE
Intervention: Bioactive glass
Description: Surgical implantation

Intervention type: DEVICE
Intervention: Beta-tricalcium phosphate (ChronOs)
Description: Surgical implantation

Intervention type: DEVICE
Intervention: Beta-tricalcium phosphate (ChronOs)
Description: Surgical implantation

Intervention type: PROCEDURE
Intervention: Autograft
Description: Surgical transplantation from iliac crest

Intervention type: PROCEDURE
Intervention: Allograft (frozen femoral head)
Description: Surgical transplantation
Study: NCT02270424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol / fluticasone (Seretide®)
Description: According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol / fluticasone (Seretide®)
Description: According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufeijianpi granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufeiyishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqizishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Bufeijianpi granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
Study: NCT00833690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inosine
Description: 500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inosine
Description: 500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
Study: NCT02468583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR 40 mg
Description: Comparator
Study: NCT03640455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal
Description: A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in anodal polarity, according to the patient's randomization arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal
Description: A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in cathodal polarity, according to the patient's randomization arm.
Study: NCT01926002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose MK-8351
Description: Single administration of low-dose MK-8351.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose MK-8351
Description: High-Dose MK-8351 administered as a single inhaled dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-8351
Description: Single-Dose Matching placebo to high-dose or low-dose MK-8351.
Study: NCT01250548

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: apremilast
Description: 30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04095403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tarp Assisted Cooling
Description: Body cooling utilizing a tarp and water

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: passive cooling
Description: Supine rest.
Study: NCT04611360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal Transcranial Direct Current Stimulation Group
Description: Experimental group were received anodal transcranial direct current stimulation and conventional training exercises for 3 days a weeks for 6 consecutive weeks on alternate days.~Anodal tDCS were given through:~i. Anodal electrode:It has been placed over primary motor cortex(ipsilesional) ii. Cathodal electrode: It has been above contralateral eye. iii. Intensity: 2mA iv Density: 0.07C/cm2 iv. Duration:20 min vi Rectangular electrodes(25cm2 ) inserted in saline soaked sponge used

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training Exercises Group
Description: Conventional physical exercises were given for 3 days a week on alternate days upto 6 weeks. It includes: progressive Conventional Training Exercises : From Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk.
Study: NCT04075357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation
Description: Amniotic membrane was located over median nerve during surgery of CTS, prior of closing.
Study: NCT01204528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar
Description: Vitamin D receptor activator (VDRA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar
Description: Vitamin D receptor activator (VDRA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zemplar
Description: Vitamin D receptor activator (VDRA)
Study: NCT03353467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Description: Endoscopic nasopharyngectomy included endoscopic resection, with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: All of the patients were received irradiation by IMRT. The target volumes were delineated according to a previously described institutional treatment protocol, which is in accordance with the International Commission on Radiation Units and Measurements reports 50 and 62.
Study: NCT02764307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constant jet nebulizer
Description: A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath enhanced nebulizer
Description: A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual-actuated nebulizer
Description: A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath-actuated nebulizer
Description: A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Study: NCT02313090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Welltang
Description: The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
Study: NCT02167646

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flap including bilateral nerve branches
Description: Two nerve branches are attached with the flap for sensory coverage
Study: NCT02540551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of radioactive tracer combined with Patent Blue
Description: Blue dye and the radioactive isotope will be injected in the remains of the ligamentum ovarium proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), just below the peritoneum. Four syringes containing 0,2 ml patent blue and 0,15 ml (20-MBq) radioactive isotope (99mTc-nanocolloid or Nanocoll®, GE Healthcare, Eindhoven, The Netherlands) will be given. After a 15-minute interval the radioactivity the SN(s) will be identified either by the mobile gamma-camera and /or gamma-probe and / or visually (blue dye) after opening the retroperitoneal space.
Study: NCT03563391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Infant Formula
Description: New Infant Formula is a specialized, nutritionally complete, nutrient-dense infant formula specifically formulated for infants with growth failure.
Study: NCT02294929

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Atrial fibrillation ablation
Description: Atrial fibrillation ablation using the Arctic Front™ Advance Cardiac CryoAblation Catheter in two balloon sizes (23mm and 28mm) for pulmonary vein isolation
Study: NCT03723512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non contrast-enhanced magnetic resonance imaging
Description: Non contrast-enhanced magnetic resonance imaging
Study: NCT04138771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An artificial intelligence system for postoperative management of cataract patients
Description: This system can detect multiple postoperative complications of cataract patients and then provide a management strategy.
Study: NCT03814395

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention
Study: NCT01568749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol formulation 1
Description: Paracetamol
Study: NCT02270424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Bufeiyishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Yiqizishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
Study: NCT02123420

Intervention type: DEVICE
Group type: OTHER
Intervention: Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)
Description: Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).~Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J\&J International, St-Stevens-Woluwe, Belgium).
Study: NCT03775018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia
Description: Acetaminophen 1g/6h iv will be administered
Study: NCT01868178

Intervention type: DEVICE
Intervention: BIS and Spectral Entropy
Description: The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
Study: NCT01683071

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 67 mg
Description: 5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 133 mg
Description: 10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 266 mg
Description: 20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 266 mg
Description: 20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty
Study: NCT01187108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: NAC 600 mg oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: NAC 600 mg oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide 250 mg oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide 250 mg oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pills
Description: 1 (or 2 in the placebo group) empty gel capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pills
Description: 1 (or 2 in the placebo group) empty gel capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: 1 (or 2 in the placebo group) empty gel capsules
Study: NCT02114567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP titration
Description: In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP titration
Description: In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi
Study: NCT00436969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthovisc
Description: Orthovisc injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Celestone (betamethasone sodium phosphate and acetate) - 2 mL
Study: NCT02608437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Description: SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
Study: NCT00926796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Four 500 mg tablets will be administered orally to equal a 2 gm dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Four 500 mg tablets will be administered orally to equal a 2 gm dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Fixed dose of 240 mg intramuscular one time for patients \>45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Description: One 320 mg tablet administered orally.
Study: NCT03072121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin pill
Description: Conventional western medicine \& shexiang baoxin pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SBP placebo
Description: Conventional western medicine \& placebo (for shexiang baoxin pill)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets
Description: 100mg tablet, one tablet daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets
Description: 100mg tablet, one tablet daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: one tablet daily. (for patients who can't use aspirin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: one tablet daily. (for patients who can't use aspirin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin Calcium
Description: 10 mg tablet, two tablets each night.
Study: NCT01796964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESBA1008 solution
Description: For intravitreal (IVT) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: For intravitreal (IVT) injection
Study: NCT03585426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.
Study: NCT01885182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Study: NCT01431443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-rich chocolate
Description: The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Chocolate
Description: Placebo intervention
Study: NCT01997294

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sequential therapy of atorvastatin
Description: 80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
Study: NCT03072121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium
Description: 10 mg tablet, two tablets each night.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: 1 tablet two times daily.
Study: NCT01997294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential therapy of atorvastatin
Description: 80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
Study: NCT00975741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OXIMAX

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASMANEX TWISTHALER
Study: NCT04532398

Intervention type: OTHER
Group type: OTHER
Intervention: Gugging swallowing screen - ICU (GUSS-ICU) index test
Description: Gugging swallowing screen - ICU (GUSS-ICU) index test:~Screening for post-extubation dysphagia: GUSS-ICU performed by 2 speech therapists independently. The GUSS-ICU model contains the core features of the original GUSS tool with the added assessment items specific to the ICU Patient (RASS score (Richmond Agitation and Sedation Scale)).~Stage one of the screen focuses on the preliminary investigation of indirect swallowing. Stage two is comprised of varying steps that directly test swallowing. This would include the administration of semisolids, water and bread with four distinct signs that were being assessed for - deglutition, coughing, drooling and voice change. The GUSS test is evaluated using a points system (0-10) which determines the severity of dysphagia and recommends a diet form that largely minimizes the risk of aspiration. (e.g. 10 points: No dysphagia = normal food).

Intervention type: OTHER
Group type: OTHER
Intervention: Flexible Endoscopic Evaluation of Swallowing (FEES) reference test
Description: Flexible Endoscopic Evaluation of Swallowing (FEES) reference test:~Flexible Endoscopic Evaluation of Swallowing (FEES) is a technique to directly view the pharynx, larynx and esophagus during swallowing. The swallowing test is carried out first with saliva and then with different consistency (liquid, pulpy, solid) and different sized swallowing portions. This reference test is performed independently from the GUSS-ICU index test.
Study: NCT00172419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin, 40 mg/day for 12 weeks
Study: NCT03059485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC/AML Fusion Vaccine
Description: The Dendritic Cell Fusion Vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Traditional care provided by the hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Traditional care provided by the hospital.
Study: NCT00305916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multislice spiral computed tomography coronary angiography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional coronary angiography